INT232511

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.27
First Reported 2005
Last Reported 2011
Negated 2
Speculated 0
Reported most in Body
Documents 7
Total Number 8
Disease Relevance 4.91
Pain Relevance 0.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (PROM1) cilium (PROM1)
Anatomy Link Frequency
stem cells 2
PROM1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Central nervous system 2 97.88 Very High Very High Very High
ischemia 1 74.64 Quite High
cytokine 12 73.48 Quite High
Inflammation 13 73.08 Quite High
chemokine 5 5.00 Very Low Very Low Very Low
palliative 4 5.00 Very Low Very Low Very Low
cINOD 4 5.00 Very Low Very Low Very Low
imagery 4 5.00 Very Low Very Low Very Low
Pain 3 5.00 Very Low Very Low Very Low
addiction 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Muscular Dystrophy 280 98.96 Very High Very High Very High
Adhesions 32 98.08 Very High Very High Very High
Cancer 176 95.68 Very High Very High Very High
Medulloblastoma 4 95.00 High High
Brain Tumor 2 94.00 High High
Fever 2 89.92 High High
Severe Combined Immunodeficiency 4 86.32 High High
Disease 57 83.76 Quite High
Glioblastoma 12 80.56 Quite High
Disease Progression 30 77.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The changes in CD133+CXCR4+CD34- percentages for individual patients are shown in Figure 4 (C and D).
Regulation (changes) of CD133
1) Confidence 0.27 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2377332 Disease Relevance 0.59 Pain Relevance 0
For these reasons, we stratified the subpopulations of circulating CD133+ stem cells based on the expression of several adhesion molecules.
Regulation (circulating) of CD133 in stem cells associated with adhesions
2) Confidence 0.27 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2377332 Disease Relevance 0.69 Pain Relevance 0.07
Moreover, we observed that the nature of the dystrophin gene mutation did not affect the levels of both CD133+CXCR4+CD34- and CD133+CXCR4+CD34+ cells in the DMD subjects analyzed in this study.
Neg (not) Regulation (affect) of CD133 associated with muscular dystrophy
3) Confidence 0.16 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2377332 Disease Relevance 0.78 Pain Relevance 0
Moreover, we observed that the nature of the dystrophin gene mutation did not affect the levels of both CD133+CXCR4+CD34- and CD133+CXCR4+CD34+ cells in the DMD subjects analyzed in this study.
Neg (not) Regulation (affect) of CD133 associated with muscular dystrophy
4) Confidence 0.16 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2377332 Disease Relevance 0.77 Pain Relevance 0
AC133 immunoreactivity was found in small, round cells or long, slender cells, which were scattered all amniotic membrane fields (Fig. 3F).
Regulation (immunoreactivity) of AC133
5) Confidence 0.15 Published 2007 Journal Yonsei Medical Journal Section Body Doc Link PMC2628011 Disease Relevance 0.16 Pain Relevance 0
A recent study by Wang et al. demonstrated the potential therapeutic use of targeting CD133 to direct therapy specifically towards CSCs.
Regulation (targeting) of CD133
6) Confidence 0.15 Published 2011 Journal Journal of Oncology Section Body Doc Link PMC2958340 Disease Relevance 0.97 Pain Relevance 0
Targeting the CSC Marker CD133
Regulation (Targeting) of CD133
7) Confidence 0.13 Published 2011 Journal Journal of Oncology Section Body Doc Link PMC2958340 Disease Relevance 0.71 Pain Relevance 0
Despite that the cells in the study of Uchida et al. [32] were described as central nervous system stem cells, it is a possibility that more immature stem cells, described by another denominator, such as CD133, were responsible for the therapeutic benefit.
Regulation (responsible) of CD133 in stem cells associated with central nervous system
8) Confidence 0.10 Published 2005 Journal GMS German Medical Science Section Body Doc Link PMC2703252 Disease Relevance 0.23 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox